Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gestodene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 8/20 | 0.93 |
| ▸ | AR | P10275 | 6/20 | 0.93 |
| ▸ | LMNA | P02545 | 5/20 | 0.93 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.93 |
| ▸ | ESR1 | P03372 | 4/20 | 0.93 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | SHBG | P04278 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gestodene SCHEMBL15263394 | 0.96 | PGR (1.00) | PGRARLMNASLC6A4ESR1 | |
| Gestodene SCHEMBL37271 | 0.96 | PGR (1.00) | PGRARLMNASLC6A4ESR1 | |
| Gestodene SCHEMBL14983004 | 0.96 | PGR (1.00) | PGRARLMNASLC6A4ESR1 | |
| Gestodene SCHEMBL16661464 | 0.96 | PGR (1.00) | PGRARLMNASLC6A4ESR1 | |
| Gestodene SCHEMBL1650027 | 0.96 | PGR (1.00) | PGRARLMNASLC6A4ESR1 | |
| Gestodene SCHEMBL2335657 | 0.96 | PGR (1.00) | PGRARLMNASLC6A4ESR1 | |
| Gestodene SCHEMBL5031715 | 0.96 | PGR (1.00) | PGRARLMNASLC6A4ESR1 | |
| Gestodene SCHEMBL4467096 | 0.95 | PGR (0.91) | PGRARLMNASLC6A4ESR1 | |
| Gestodene SCHEMBL4473794 | 0.91 | PGR (0.83) | PGRARLMNASLC6A4ESR1 | |
| Gestodene SCHEMBL8460856 | 0.90 | PGR (0.82) | PGRARLMNASLC6A4ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043943-A1 | Method for the management of incontinence | ALZA CORPORATION | 2004-03-04 | — | — | US | claimed |
| US-20040037881-A1 | Method for the management of incontinence | ALZA CORPORATION | 2004-02-26 | — | — | US | claimed |
| US-6262115-B1 | ADMITTING ORALLY INTO THE PATIENT A DOSAGE FORM OF OXYBUTYNIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALT, THAT IS ADMINISTERED ONCE-A-DAY AS SUSTAINED-RELEASE FORM FOR MANAGEMENT OF INCONTINENCE | ALZA COPORATION | 2001-07-17 | — | — | US | claimed |
| US-20010005728-A1 | Method for the management of incontinence | ALZA CORPORATION | 2001-06-28 | — | — | US | claimed |
| US-5770227-A | Progesterone replacement therapy | ALZA CORPORATION (US) | 1998-06-23 | — | — | US | claimed |
| US-5633011-A | Progesterone replacement therapy | ALZA CORPORATION (US) | 1997-05-27 | — | — | US | claimed |
| CN-112533626-A | Silk-based product formulations and methods of use | 柯坤生物科技公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20120015917-A1 | Use of Estrogenic Compounds in Combination with Progestogenic Compounds in Hormone-Replacement Therapy | PANTARHEI BIOSCIENCE B.V. (NL) | 2012-01-19 | — | — | US | disclosed |
| US-8071576-B2 | Fewer side effects; usable for longer period of time; lower recurrence rates after discontinuation; combination of progestogen and androgen components; kits | PANTARHEI BIOSCIENCE B.V. (NL) | 2011-12-06 | — | — | US | disclosed |
| EP-2044942-A1 | Pharmaceutical preparation for continuous hormonal treatment over a period of 21-28 days comprising two ethinylestradio or estradio and drospirenone compositions | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080312198-A1 | PHARMACEUTICAL PRODUCTS CONTAINING HORMONES AND A 25-HYDROXY VITAMIN D COMPOUND | RODRIGUEZ GUSTAVO C | 2008-12-18 | — | — | US | disclosed |
| US-20080312197-A1 | PHARMACEUTICAL PRODUCTS CONTAINING HORMONES AND A 25-HYDROXY VITAMIN D COMPOUND | RODRIGUEZ GUSTAVO C | 2008-12-18 | — | — | US | disclosed |
| US-20080234240-A1 | Extended Use Combination Comprising Estrogens And Progestins | SCHERING AG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-5620705-A | Progestin tablet | ALZA CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
| US-5595759-A | Process for providing therapeutic composition | ALZA CORPORATION (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0500793-B1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORP (US) | 1993-11-03 | — | — | EP | disclosed |
| US-5200197-A | Contraceptive pill | ALZA CORPORATION (US) | 1993-04-06 | — | — | US | disclosed |
| EP-0500793-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL. | ALZA CORP (US) | 1992-09-02 | — | — | EP | disclosed |
| US-5098714-A | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1992-03-24 | — | — | US | disclosed |
| WO-1991007173-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312197-A1 | PHARMACEUTICAL PRODUCTS CONTAINING HORMONES AND A 25-HYDROXY VITAMIN D COMPOUND | CYP24A1, CYP2R1, VDR | PGR 22/4885AR 134/4885LMNA 4140/4885 |
| US-20080312198-A1 | PHARMACEUTICAL PRODUCTS CONTAINING HORMONES AND A 25-HYDROXY VITAMIN D COMPOUND | CYP24A1, CYP2R1, VDR | PGR 22/4885AR 134/4885LMNA 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.